{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:57:06Z","timestamp":1791809826118,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"NHS England"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s41669-025-00637-4","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:16:29Z","timestamp":1769181389000},"page":"577-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-5031","authenticated-orcid":false,"given":"Masood","family":"Moghul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deokhee","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Westaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netty","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kierkegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas David","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"637_CR1","unstructured":"Cancer Registration Statistics. 2020. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics\/england-2020\/deaths-from-cancer-increased-with-deprivation#:~:text=Thegap between the least,(255 per 100%2C000 people)."},{"key":"637_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pros.24320","volume":"82","author":"KC Madhav","year":"2022","unstructured":"Madhav KC, Oral E, Rung AL, et al. Neighborhood deprivation and risk of mortality among men with prostate cancer: findings from a long-term follow-up study. Prostate. 2022;82:783\u201392.","journal-title":"Prostate"},{"key":"637_CR3","unstructured":"Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today. Accessed 19 June 2023."},{"key":"637_CR4","unstructured":"Cancer Research UK Early Diagnosis Data Hub. https:\/\/crukcancerintelligence.shinyapps.io\/EarlyDiagnosis\/."},{"key":"637_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","journal-title":"Lancet"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310\u20139.","journal-title":"N Engl J Med"},{"key":"637_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1740774510374091","volume":"7","author":"PF Pinsky","year":"2010","unstructured":"Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7:303\u201311.","journal-title":"Clin Trials"},{"key":"637_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43\u201351.","journal-title":"Eur Urol"},{"key":"637_CR9","doi-asserted-by":"crossref","unstructured":"The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778\u201386.","DOI":"10.1016\/S0140-6736(12)61611-0"},{"key":"637_CR10","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126\u201337.","journal-title":"N Engl J Med"},{"key":"637_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt O, Godtman RA, Jiborn T, et al. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol. 2024;85:207\u201314.","journal-title":"Eur Urol"},{"key":"637_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","volume":"29","author":"EM Rencsok","year":"2020","unstructured":"Rencsok EM, Bazzi LA, McKay RR, et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomark Prev. 2020;29:1374\u201380.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"637_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"637_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41391-021-00438-w","volume":"25","author":"TH Newman","year":"2022","unstructured":"Newman TH, Stroman L, Hadjipavlou M, et al. EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Prostate Cancer Prostatic Dis. 2022;25:283\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"637_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.euros.2023.05.011","volume":"53","author":"O M\u00e1jek","year":"2023","unstructured":"M\u00e1jek O, Babjuk M, Roobol MJ, et al. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration. Eur Urol Open Sci. 2023;53:106\u20138.","journal-title":"Eur Urol Open Sci"},{"key":"637_CR16","unstructured":"Europa Uoma\u2014News Page. 2024. https:\/\/www.europa-uomo.org\/news\/national-prostate-screening-programme-underway-in-czech-republic\/#:~:text=ThenewCzechnationalscreening,toaurologistifneccessary. Accessed 29 Aug 29 2024."},{"key":"637_CR17","unstructured":"National Health Service of Latvia. Preventive cancer screening. 2023. https:\/\/www.vmnvd.gov.lv\/en\/preventive-cancer-screening?utm_source=https%3A%2F%2Fwww.google.com%2F. Accessed 29 Aug 2024."},{"key":"637_CR18","unstructured":"Office for Health Improvement and Disparities. Public health profile. 2023. https:\/\/fingertips.phe.org.uk. Accessed 28 Sept 2024."},{"key":"637_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/jms.9.3.104","volume":"9","author":"K McCaffery","year":"2002","unstructured":"McCaffery K, Wardle J, Nadel M, Atkin W. Socioeconomic variation in participation in colorectal cancer screening. J Med Screen. 2002;9:104\u20138.","journal-title":"J Med Screen"},{"key":"637_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017729","volume":"7","author":"GJ Young","year":"2017","unstructured":"Young GJ, Harrison S, Turner EL, et al. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. BMJ Open. 2017;7:e017729.","journal-title":"BMJ Open"},{"key":"637_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.pcan.4500646","volume":"6","author":"B Little","year":"2003","unstructured":"Little B, Ho KJ, Gormley G, Young M. PSA testing in general practice. Prostate Cancer Prostatic Dis. 2003;6:154\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"637_CR22","unstructured":"National Institute for Health and Care Excellence. NICE guideline NG12: suspected cancer: recognition and referral [A] Evidence reviews for diagnostic accuracy of prostate specific antigen (PSA) thresholds for referring people with suspected prostate cancer. NICE 2021."},{"key":"637_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3974-1","volume":"18","author":"S Sanghera","year":"2018","unstructured":"Sanghera S, Coast J, Martin RM, Donovan JL, Mohiuddin S. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer. 2018;18:1\u201315.","journal-title":"BMC Cancer"},{"key":"637_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40258-016-0278-6","volume":"15","author":"A Keller","year":"2017","unstructured":"Keller A, Gericke C, Whitty JA, et al. A cost-utility analysis of prostate cancer screening in Australia. Appl Health Econ Health Policy. 2017;15:95\u2013111.","journal-title":"Appl Health Econ Health Policy"},{"key":"637_CR25","unstructured":"Health profile for England: 2018. Chapter 5 inequalities in health. Public Health England. https:\/\/www.gov.uk\/government\/publications\/health-profile-for-england-2018\/chapter-5-inequalities-in-health?utm_source=chatgpt.com#contents."},{"key":"637_CR26","unstructured":"National Prostate Cancer Audit Short Report: Patient and Tumour Characteristics Associated with Metastatic Prostate Cancer at Diagnosis in England. 2022."},{"key":"637_CR27","volume":"211","author":"M Moghul","year":"2024","unstructured":"Moghul M, Croft F, Mutch F, Westaway E, Kinsella N, Cahill D, et al. The man van project: second phase interim results. J Clin Oncol. 2024;211:e1288.","journal-title":"J Clin Oncol"},{"key":"637_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.5","author":"M Moghul","year":"2025","unstructured":"Moghul M, Croft F, Mutch F, et al. The man van phase 2 results: mobile targeted case finding for prostate cancer. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/jco.2025.43.5.","journal-title":"J Clin Oncol"},{"key":"637_CR29","unstructured":"GOV.UK. Economic evaluation: health economic studies. 2020. https:\/\/www.gov.uk\/guidance\/economic-evaluation-health-economic-studies. Accessed 31 Aug 2024."},{"key":"637_CR30","unstructured":"GOV.UK. Cost consequence analysis: health economic studies. 2020. https:\/\/www.gov.uk\/guidance\/cost-consequence-analysis-health-economic-studies. Accessed 31 Aug 2024."},{"key":"637_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/clinpract13040078","volume":"13","author":"M Moghul","year":"2023","unstructured":"Moghul M, Cazzaniga W, Croft F, Kinsella N, Cahill D, James ND. Mobile health solutions for prostate cancer diagnostics\u2014a systematic review. Clin Pract. 2023;13:863\u201372.","journal-title":"Clin Pract"},{"key":"637_CR32","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1002\/cam4.3387","volume":"9","author":"A Jatho","year":"2020","unstructured":"Jatho A, Mugisha NM, Kafeero J, Holoya G, Okuku F, Niyonzima N. Mobile cancer prevention and early detection outreach in Uganda: partnering with communities toward bridging the cancer health disparities through \u201casset-based community development model.\u201d Cancer Med. 2020;9:7317\u201329.","journal-title":"Cancer Med"},{"key":"637_CR33","doi-asserted-by":"crossref","unstructured":"Jones C, Charles JM, Edwards RT. Identification, measurement, and valuation of resource use in economic evaluations of public health interventions. In: Applied health economics for public health practice and research. 2019. p. 107\u201330.","DOI":"10.1093\/med\/9780198737483.003.0005"},{"key":"637_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35169","author":"M Moghul","year":"2024","unstructured":"Moghul M, Tran A, Croft F, et al. The man van: a pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer. Int J Cancer. 2024. https:\/\/doi.org\/10.1002\/ijc.35169.","journal-title":"Int J Cancer"},{"key":"637_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00019053-199813030-00002","volume":"13","author":"JA Mauskopf","year":"1998","unstructured":"Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13:277\u201388.","journal-title":"Pharmacoeconomics"},{"key":"637_CR36","doi-asserted-by":"publisher","unstructured":"Jones, Karen; Burns A. Costs of health and social care 2021, First edit. University of Kent; 2021 https:\/\/doi.org\/10.22024\/UniKent\/01.02.92342.","DOI":"10.22024\/UniKent\/01.02.92342"},{"key":"637_CR37","doi-asserted-by":"publisher","unstructured":"Jones K, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan AFD, Forder J, Gao M, Hinde S, Markham S, Premji S, Teo H. Unit costs of health and social care 202. 2023 https:\/\/doi.org\/10.22024\/UniKent\/01.02.105685.","DOI":"10.22024\/UniKent\/01.02.105685"},{"key":"637_CR38","unstructured":"NICE. Stockholm3 for prostate cancer screening. 2022. https:\/\/www.nice.org.uk\/advice\/mib303\/resources\/stockholm3-for-prostate-cancer-screening-pdf-2285967566184901. Accessed 5 Sept 2024."},{"key":"637_CR39","unstructured":"NHS supply chain catalogue. 2024. https:\/\/www.supplychain.nhs.uk. Accessed 5 Sept 2024."},{"key":"637_CR40","unstructured":"Centre NCG. Preoperative tests Routine preoperative tests for elective surgery. 2015."},{"key":"637_CR41","unstructured":"NHS digital. https:\/\/digital.nhs.uk\/services\/nhs-notify\/text-message-pricing#:~:text=Itcosts2.27pence(plus,usecertainsignsandsymbols. Accessed 5 Sept 2024."},{"key":"637_CR42","unstructured":"https:\/\/www.theenergyshop.com\/guides\/electricity-cost-calculator. ."},{"key":"637_CR43","unstructured":"Vodafone UK. www.vodafone.co.uk. Accessed 6 Sept 2024."},{"key":"637_CR44","unstructured":"AutoExpress. https:\/\/www.autoexpress.co.uk\/iveco\/daily. Accessed 5 Sept 2024."},{"key":"637_CR45","unstructured":"RAC. https:\/\/www.rac.co.uk\/drive\/advice\/fuel-watch\/. Accessed 5 Sept 2024."},{"key":"637_CR46","unstructured":"DVLA. https:\/\/www.gov.uk\/government\/publications\/heavy-goods-vehicle-fees\/vehicle-test-and-certificate-costs-lorries-and-trailers-at-authorised-testing-facilities#hgv-mot-tests. Accessed 6 Sept 2024."},{"key":"637_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2016-011356","volume":"6","author":"P Nderitu","year":"2016","unstructured":"Nderitu P, Van Hemelrijck M, Ashworth M, et al. Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested? BMJ Open. 2016;6:1\u20139.","journal-title":"BMJ Open"},{"key":"637_CR48","unstructured":"ONS. Estimates of the population for the UK, England, Wales, Scotland, and Northern Ireland. 2022. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland. Accessed 10 Sept 2024."},{"key":"637_CR49","unstructured":"The King\u2019s Fund: Key facts and figures about the NHS. 2025. https:\/\/www.kingsfund.org.uk\/insight-and-analysis\/data-and-charts\/key-facts-figures-nhs (accessed July 7, 2025)."},{"key":"637_CR50","unstructured":"NHS England. NHS Breast Screening Programme, England 2021\u201322. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/breast-screening-programme\/england---2021-22. Accessed 11 Sept 2024."},{"key":"637_CR51","unstructured":"Solihull.gov. NHS breast screening in Solihull. https:\/\/www.solihull.gov.uk\/health-and-wellbeing\/NHS-breast-screening-solihull#:~:text=TheNHSprovidesitsfree,amammogramevery3years. Accessed 11 Sept 2024."},{"key":"637_CR52","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jama.280.20.1757","volume":"280","author":"Group TCDCDC-ES","year":"1998","unstructured":"Group TCDCDC-ES. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757\u201363.","journal-title":"JAMA"},{"key":"637_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2023","unstructured":"Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023;47:26\u201343.","journal-title":"Diabetes Care"},{"key":"637_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/CMED.S20906","volume":"8","author":"A Liebl","year":"2015","unstructured":"Liebl A, Khunti K, Orozco-Beltran D, Yale J-F. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clin Med Insights Endocrinol Diabetes. 2015;8:13\u20139.","journal-title":"Clin Med Insights Endocrinol Diabetes"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00637-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:57:36Z","timestamp":1779368256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00637-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00637-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Man Van project has ethical approval from Wales Research Ethics Committee (REC) 6. REC reference: 22\/WA\/0113.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The specific author contributions are shown here following CRediT (Contribution Roles Taxonomy): MM: Conceptualisation, Data curation, Formal analysis, Funding acquisition, Investigation, Resources, Methodology, Project administration, Visualisation, Writing\u2014original draft preparation, Writing\u2014review and editing. DY: Data curation, Methodology, Formal analysis, Validation, Writing\u2014review and editing. FC: Conceptualisation, Data curation, Investigation, Resources, Project administration, Writing\u2014review and editing. FM: Conceptualisation, Data curation, Investigation, Writing\u2014review and editing. EW: Conceptualisation, Data curation, Investigation, Writing\u2014review and editing. NK: Conceptualisation, Data curation, Formal analysis, Investigation, Methodology, Resources, Project administration, Supervision, Writing\u2014review and editing. PK: Conceptualisation, Methodology, Project administration, Supervision, Writing\u2014review and editing. DC: Conceptualisation, Methodology, Project administration, Supervision, Writing\u2014review and editing. NDJ: Conceptualisation, Funding acquisition, Methodology, Resources, Project administration, Supervision, Writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}